Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of multidrug-resistant (MDR-PA) osteomyelitis with Ceftolozane/tazobactam: a retrospective study

Trial Profile

Treatment of multidrug-resistant (MDR-PA) osteomyelitis with Ceftolozane/tazobactam: a retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Osteomyelitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2018 New trial record
    • 07 Oct 2018 Results assessing clinical and microbiologic outcomes of patients treated with with C/T for multidrug-resistant (MDR-PA) osteomyelitis, presented at the IDWeek 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top